The Chinese vaccine against coronavirus is losing points, and the “second-rate” vaccine, as the Russian one was previously called, “Sputnik V”, on the contrary, is rapidly growing in the world ranking. This opinion was expressed by the former head of the economic intelligence service of the research bureau under the Japanese cabinet of ministers (from 2003 to 2016), and now the chief analyst and professor at the Research Institute of Economics, Industry and Trade under the Ministry of Economy and Industry of the country, Kazuhiko Fuji, to the news portal Yahoo News Japan.
With the confirmed ability of the novel coronavirus mutants to overcome antibody resistance, the vaccination strategy is expected to change. As a result, as many vaccines as possible should be available to combat mutant viruses, Fuji said. He drew attention to the fact that now the world uses the American matrix vaccines Pfizer and Moderna, the British AstraZeneca and the Russian Sputnik V, which are vector-type vaccines, as well as traditional inactivated vaccines presented by two Chinese companies.
Matrix vaccines are highly effective, he said, while Chinese products have a bad reputation. Its proven efficacy is about 50%, the minimum cutoff value set by the World Health Organization (WHO).
In his opinion, “we should consider attracting Sputnik V in Japan in the medium term.”